ClinicalTrials.gg
TerminatedNCT01179737Updated May 1, 2014Results posted

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

A Phase 2 interventional study of Nilotinib and Placebo to nilotinib in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Terminated at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated due to serious adverse event (SAE)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.

Enrollment
7th of 12
23 · median 27
Started
2010
with 1 other
Phase 2
5 of 12
none open now
Registered
4th of 12
by date

Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 7th largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 2, and was the 4th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pulmonary Arterial Hypertension by Novartis, or all of them as a file.
02

Study summary

The purpose of this trial was to establish the safety, tolerability and PK of nilotinib in this population and to test the hypothesis that 6 months treatment with nilotinib will significantly reduce pulmonary artery resistance.

Read the detailed description

The purpose of this trial was to establish the safety, tolerability and PK of nilotinib in this population and to test the hypothesis that 6 months

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary Arterial Hypertension
  • Nilotinib
  • 6MWD
  • Pulmonary Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • World Health Organization (WHO) Functional Class II or III
  • 6MWD ≥ 150 m and ≤ 450 m at screening
  • Current diagnosis of PAH according to Dana Point 2008 Meeting
  • Inadequate clinical response on one or more class(es) of PAH drug
  • Stabilization of pulmonary hypertension medications for ≥ 2 months on approved therapeutic dose of at least one PAH drug and still symptomatic with WHO functional Class II or III performance.

Exclusion criteria

Exclusion Criteria:

  • Women of not practicing
  • In treatment with chronic nitric oxide therapy
  • Pre-existing lung disease
  • Use of drugs prolonging the or strong inhibitors
  • Long QT syndrome or QTc > 450 ms males; > 470 ms females.
  • WHO Class IV
  • Pulmonary capillary wedge pressure > 15 mm Hg
  • Other diagnosis of PAH in WHO Diagnostic Group 1
  • PAH associated with: venous hypertension (WHO Diagnostic Group II), hypoxia (WHO Diagnostic Group III), chronic pulmonary thromboembolic disease (WHO Diagnostic Group IV) or other miscellaneous causes (WHO Diagnostic Class V, which includes sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels)
  • Thrombocytopenia \< 50 x109/L (50 x 103/µL)
  • Uncontrolled systemic arterial hypertension, systolic > 160 mm Hg or diastolic >90 mm Hg
  • Any advanced, severe, or unstable disease of any type that may interfere with the primary and secondary endpoint evaluations.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Participants in cohort 1 were assigned to receive nilotinib 50 mg during 14 days, followed by 150 mg during 14 days, followed by 300 mg during 140 days. Participants in cohort 2 were assigned to receive nilotinib 300 mg during 168 days

    Drug: Nilotinib

  • Placebo comparator
    Placebo

    Participants were assigned to receive placebo to nilotinib to match 50 mg and 150 mg capsules during 168 days.

    Drug: Placebo to nilotinib

Interventions

  • Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.

  • DrugPlacebo to nilotinib

    Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day

06

What researchers measure

Primary outcomes

  1. Change in Pulmonary Vascular Resistance (PVR)

    Change in pulmonary vascular resistance is measured via right heart catheter assessment according to local hospital procedures. It assesses several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Vascular Resistance (PVR). Study was prematurely terminated and not powered for efficacy.

    Time frame: 168 days

Secondary outcomes

  1. Change in Six-Minute Walk Distance (6MWD) From Baseline

    During standardized walk course participants are connected to a portable pulse oximeter via a finger probe and instructed to walk at a comfortable speed for as far as they could manage in 6 minutes. Study was prematurely terminated and efficacy data were not analyzed or summarized

    Time frame: Baseline, 168 days

  2. Total Number of Adverse Events and Serious Adverse Events

    Adverse events were summarized by the number of patients having any adverse event overall and presented in the safety section. Study was prematurely terminated.

    Time frame: 168 days

07

Results

Posted Feb 27, 2014

Participant flow

23 participants were enrolled into the study (15 in cohort 1; 8 in cohort 2) 8 participants completed cohort 1 and 6 of these participants moved into cohort 1expansion. Of the 5 participants that completed Cohort 1 expansion; 3 participants went into an Extension. None of the participants completed treatment as trial was terminated

Cohort 1 & Cohort 2
Participant flow — Cohort 1 & Cohort 2
MilestoneCohort 1: NilotinibCohort 1: PlaceboCohort 2: NilotinibCohort 2: Placebo
Started12344
Completed7100
Not completed5244
Withdrew: Adverse event3110
Withdrew: Withdrew consent2000
Withdrew: Administrative problems0024
Withdrew: Death0010
Withdrew: Withdrew consent without eos 1 visit0100
Cohort 1 & Cohort 2 Expansion
Participant flow — Cohort 1 & Cohort 2 Expansion
MilestoneCohort 1: NilotinibCohort 1: PlaceboCohort 2: NilotinibCohort 2: Placebo
Started5100
Completed4100
Not completed1000
Withdrew: Death1000
Extension
Participant flow — Extension
MilestoneCohort 1: NilotinibCohort 1: PlaceboCohort 2: NilotinibCohort 2: Placebo
Started3000
Completed0000
Not completed3000
Withdrew: The study was terminated3000

Outcome measures

SecondaryChange in Six-Minute Walk Distance (6MWD) From Baseline

During standardized walk course participants are connected to a portable pulse oximeter via a finger probe and instructed to walk at a comfortable speed for as far as they could manage in 6 minutes. Study was prematurely terminated and efficacy data were not analyzed or summarized

Time frame:
Baseline, 168 days

No measurements were reported for this outcome.

PrimaryChange in Pulmonary Vascular Resistance (PVR)

Change in pulmonary vascular resistance is measured via right heart catheter assessment according to local hospital procedures. It assesses several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Vascular Resistance (PVR). Study was prematurely terminated and not powered for efficacy.

Time frame:
168 days

No measurements were reported for this outcome.

SecondaryTotal Number of Adverse Events and Serious Adverse Events

Adverse events were summarized by the number of patients having any adverse event overall and presented in the safety section. Study was prematurely terminated.

Time frame:
168 days

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events were collected over the duration of treatment 140 days for cohort 1, 168 days for cohort 2 and up to 1092 days in the extension study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Nilotinib—7/12 (58.3%)12/12 (100%)
Cohort 1: Placebo—1/3 (33.3%)1/3 (33.3%)
Cohort 2: Nilotinib—2/4 (50%)3/4 (75%)
Cohort 2: Placebo—1/4 (25%)4/4 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventCohort 1: NilotinibCohort 1: PlaceboCohort 2: NilotinibCohort 2: Placebo
Clostridial infectionInfections and infestations0/121/30/40/4
Infusion site infectionInfections and infestations0/121/30/40/4
SepsisInfections and infestations0/121/30/40/4
Disseminated intravascular coagulationBlood and lymphatic system disorders0/120/31/40/4
Cardiogenic shockCardiac disorders0/120/31/40/4
Torsade de pointesCardiac disorders0/120/31/40/4
Gastric ulcer haemorrhageGastrointestinal disorders0/120/31/40/4
Cholecystitis chronicHepatobiliary disorders3/120/30/40/4
CellulitisInfections and infestations0/120/31/40/4
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders0/120/30/41/4
Most frequent other events
Showing 10 of 142
Most frequent other events
EventCohort 1: NilotinibCohort 1: PlaceboCohort 2: NilotinibCohort 2: Placebo
NauseaGastrointestinal disorders3/121/33/41/4
VomitingGastrointestinal disorders3/120/33/40/4
HeadacheNervous system disorders6/121/33/41/4
FatigueGeneral disorders6/120/30/40/4
Blood bilirubin increasedInvestigations0/120/32/40/4
SyncopeNervous system disorders0/120/30/42/4
RashSkin and subcutaneous tissue disorders3/120/32/40/4
PancytopeniaBlood and lymphatic system disorders1/121/30/40/4
DiarrhoeaGastrointestinal disorders4/121/31/40/4
Upper respiratory tract infectionInfections and infestations1/121/30/41/4

Baseline characteristics

an end of study evaluation was only available for 14 of these patients

Age, Continuous
Age, Continuous(Years)Cohort 1: NilotinibCohort 1: PlaceboCohort 2: NilotinibCohort 2: PlaceboTotal
Mean52 ± 13.160 ± 6.131 ± 14.633 ± 10.232 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: NilotinibCohort 1: PlaceboCohort 2: NilotinibCohort 2: PlaceboTotal
Female1034320
Male20013
08

Study locations

13 sites
  • Novartis Investigative Site
    Boston, Massachusetts 02118, United States
  • Novartis Investigative Site
    Ann Arbor, Michigan 48109-0391, United States
  • Novartis Investigative Site
    Chapel Hill, North Carolina 27599, United States
  • Novartis Investigative Site
    Cleveland, Ohio 44195, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37232-2573, United States
  • Novartis Investigative Site
    Calgary, Alberta T6G 2B7, Canada
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Marburg, 35039, Germany
  • Novartis Investigative Site
    Seoul, Korea 120-752, Korea, Republic of
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 168752, Singapore
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2010
First posted
Aug 11, 2010
Start
Jul 2010
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results first posted
Feb 27, 2014
Last update
May 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01179737
Responsible party
Sponsor
First posted
Aug 11, 2010
Start date
Jul 2010
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
Feb 27, 2014
Last update
May 1, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion